$51.7 million in sales and $10.1 million adjusted EBITDA marked Eutrepia's first full launch quarter.
| Quarter | Q3 FY25 |
|---|---|
| Call date | 2025-11-03 |
| Length | 32 minutes |
| EPS | $-0.04 |
| Revenue | $54.3M |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q2 FY26 · Q4 FY25
Read the full Q3 FY25 earnings call transcript
All LQDA earnings · Back to LQDA overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.